title: Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration.
abstract: Fluorodopa (FDOPA) and fluorodeoxyglucose (FDG) PET was performed in six patients in early stages of corticobasal degeneration (CBD) and compared to Parkinson's disease (PD) patients with a similar degree of bradykinesia and rigidity and to healthy controls. Statistical parametric mapping analysis comparing CBD to controls showed metabolic decrease in premotor, primary motor, supplementary motor, primary sensory, prefrontal, and parietal associative cortices, and in caudate and thalamus contralateral to the side of clinical signs. Except for the prefrontal regions a similar metabolic pattern was observed when CBD was compared to PD. Putamen FDOPA uptake was decreased in both CBD and PD. Caudate FDOPA uptake in CBD patients was decreased contralateral to clinical signs when compared to controls, but was higher than in PD. In early stages of CBD, FDOPA and FDG PET patterns differed from those observed in PD. In CBD the asymmetry in FDOPA uptake was less pronounced than that of clinical signs or metabolic impairment.
authors.affiliation: Cyclotron Research Center, and Department of Neurology, University of Liège, Belgium. laureys@pet.crc.ulg.ac.be
authors.forename: S
authors.initials: S
authors.lastname: Laureys
authors.forename: E
authors.initials: E
authors.lastname: Salmon
authors.forename: G
authors.initials: G
authors.lastname: Garraux
authors.forename: P
authors.initials: P
authors.lastname: Peigneux
authors.forename: C
authors.initials: C
authors.lastname: Lemaire
authors.forename: C
authors.initials: C
authors.lastname: Degueldre
authors.forename: G
authors.initials: G
authors.lastname: Franck
mesh_terms: D000368:Aged; D001479:Basal Ganglia / Q000000981:diagnostic imaging / Q000378:metabolism*; D001927:Brain Diseases / Q000000981:diagnostic imaging / Q000378:metabolism*; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000000981:diagnostic imaging / Q000378:metabolism*; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012016:Reference Values; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine; D005947:Glucose